抗疟药使用与狼疮肾炎肾外损害累积:纵向队列研究
该研究基于多伦多狼疮诊所1970-2024年前瞻性随访队列,回顾性分析352例活检证实的狼疮肾炎患者,发现抗疟药使用与肾外损害累积风险降低独立相关(HR 0.51,95%CI 0.37-0.72),且在各基线肾外SDI亚组中均显著。
要点
- 抗疟药使用与肾外损害累积风险降低独立相关(HR 0.51)。
- 保护效应在基线SDI=0及SDI≥1患者中均显著。
- 肾外损害常见,327例中151例(46.2%)发生。
核心结论
- 在活检证实的狼疮肾炎患者中,抗疟药治疗与肾外损害累积风险显著降低独立相关。
研究设计与样本
- 回顾性分析多伦多狼疮诊所1970-2024年前瞻性随访队列中352例活检证实的狼疮肾炎患者,抗疟药使用作为时间依赖变量,采用多变量Cox比例风险模型分析。
主要发现
- 352例患者中位年龄34.1岁,男性占14.5%,中位随访9.6年(IQR 4.9-16.6)。
- 基线时47.7%使用抗疟药,第一年期间58.5%,第5年时67.9%。
- 327例有完整SDI数据的患者中,151例(46.2%)发生肾外损害,中位时间4.1年(IQR 1.8-8.9)。
- 多变量模型中,抗疟药使用对肾外损害累积独立保护(HR 0.51,95%CI 0.37-0.72)。
- 保护效应在所有基线肾外SDI亚组中均显著,包括SDI=0和SDI≥1患者。
关键数值与推荐
- 肾外损害定义为肾外SLICC/ACR损害指数(SDI)任何增加(≥1)。
临床怎么用
- 对于活检证实的狼疮肾炎患者,抗疟药使用可能有助于减少肾外损害累积,支持其在该人群中的持续应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Antimalarial agents, particularly hydroxychloroquine, are fundamental in SLE management. While their renal benefits in lupus nephritis (LN) are recognized, their corresponding role in reducing extra-renal damage is less defined. This study examined the association between antimalarial use and extra-renal damage accrual in biopsy-confirmed LN. METHODS: This was a retrospective analysis of a prospectively followed cohort of patients with biopsy-confirmed LN enrolled in the University of Toronto Lupus Clinic (1970-2024). Extra-renal damage was defined as any increase (≥1) in the extra-renal SLICC/ACR Damage Index (SDI). Antimalarial use was analyzed as a time-dependent variable. Associations were assessed using multivariable Cox proportional hazards models. RESULTS: Among 352 patients, the median age was 34.1 years, 14.5% were male, and the median follow-up was 9.6 years [IQR 4.9-16.6]. Antimalarials were used by 47.7% at baseline, 58.5% during the first year, and 67.9% by year 5. Among 327 patients with complete SDI data, extra-renal damage occurred in 151 patients (46.2%) with a median time of 4.1 years [1.8-8.9]. In multivariable models, antimalarial use was independently protective against extra-renal damage accrual (HR 0.51, 95% CI 0.37-0.72). This protective effect remained significant across all baseline extra-renal SDI subgroups, including in patients with SDI = 0 and those with SDI ≥1. CONCLUSIONS: Extra-renal damage is common in patients with LN. In this population, antimalarial therapy was associated with a significant protective effect against extra-renal damage. These findings extend the benefits of antimalarials beyond renal protection and reinforce their essential role in reducing damage accrual in SLE patients with LN.
引用
- Kharouf F, Mehta P, Li Q, et al. Antimalarial use and extra-renal damage accrual in lupus nephritis: a longitudinal cohort study. Rheumatology (Oxford). 2026. PMID: 41936091. doi:10.1093/rheumatology/keag165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。